



TRUCHECK



EARLY DETECTION OF MULTIPLE CANCERS

TruCheck has the ability to detect 77 cancer which account for 81% of all cancer cases and 84% of all cancer related deaths in Europe.

NON INVASIVE HEALTH CHECK

TruCheck is a non-invasive liquid biopsy, and offers a fast frictionless and patient friendly option for cancer screening.

FDA BREAKTHROUGH DESIGNATION

TruCheck offers sensitivity and specificity of over 90% and has been granted FDA breakthrough designation. Given to new technologies that offer significant advantages over current alternatives.



Trucheck™ in Breast Cancer Detection


	Trucheck™	Mammography ¹
Sensitivity	88.2%	86.9%
Specificity	100.0%	88.9%
PPV	100.0%	69.6% ²
NPV	99.9%	95.9% ⁴¹



Trucheck™ in Prostate Cancer Detection

	Trucheck™	PSA ⁵
Sensitivity	85.6%	90.0%
Specificity	100.0%	19.7%
PPV	100.0%	33.9%
NPV	99.9%	81.0%

METHOD



CIRCULATING TUMOUR CELLS

Trucheck detects circulating tumour cells (CTCs) and clusters of these CTCs which are released by malignant tumours, but not from non-cancerous (normal / benign tumour / inflammatory) tissue. CTCs are not seen in the blood of healthy individuals.



NEGATIVE ENRICHMENT

Trucheck employs an epigenetically activating medium (EAM) which negatively enriches CTCs via the cancer hallmark of evading apoptosis. When isolated cells are treated with the EAM, all non-malignant cells are killed by apoptosis and any cancer derived malignant cells (CTCs) survive.



TISSUE & ORGAN MARKERS

In addition to overcoming the malignant v/s non-malignant conundrum by primary negative enrichment, Trucheck also incorporates evaluation of tissue organ of origin specific markers through ICC, which are known to be expressed in cancer cells and mostly absent in normal cells.

TRUCHECK OPTIONS

02

TRUCHECK DIABETES

People with type 2 diabetes are twice as likely to be diagnosed with pancreatic or liver cancers as compared to those without type 2 diabetes.

TruCheck diabetes can be used for the detection of cancers in the Pancreas, Liver, Gallbladder, Kidney, Bladder and Colorectum.

01

TRUCHECK SINGLE ORGAN

TruCheck single organ offers a cost-effective option to those with a genetic predisposition, or familial history, of a single specific cancer type.

Breast - Prostate - Colorectal and Stomach

03

TRUCHECK INTELLI

TruCheck Intelli can determine the presence of malignancy in over 70 different types of cancer. It also has the ability to determine which organ system the tumour cells originate from.

Clinically validated in a study of over 20,000 participants.

CLINICAL VALIDATION

	Cancer v/s Asymptomatic	Cancer v/s Benign
Sensitivity	85.74% (85.18% - 86.29%)	85.74% (85.18% - 86.29%)
Specificity	100.0% (99.97% - 100%)	99.29% (98.34% - 99.77%)
Accuracy	99.97% (99.94% - 99.99%)	94.82% (94.46% - 95.15%)
PPV	100.0%	98.34% (96.11% - 99.30%)
NPV	99.97% (99.97% - 99.97%)	93.39% (93.15% - 93.63%)